Zobrazeno 1 - 10
of 86
pro vyhledávání: '"Marielle Chiron"'
Autor:
Kamlesh Bisht, Taro Fukao, Marielle Chiron, Paul Richardson, Djordje Atanackovic, Eduardo Chini, Wee Joo Chng, Helgi Van De Velde, Fabio Malavasi
Publikováno v:
Cancer Medicine, Vol 12, Iss 20, Pp 20332-20352 (2023)
Abstract Background CD38 has been established as an important therapeutic target for multiple myeloma (MM), for which two CD38 antibodies are currently approved—daratumumab and isatuximab. CD38 is an ectoenzyme that degrades NAD and its precursors
Externí odkaz:
https://doaj.org/article/11c9e5f0da7846b4a4ba574aa7ba86ce
Autor:
Paul G. Richardson, Thierry Facon, William I. Bensinger, Xavier Leleu, Frank Campana, Sandrine Macé, Marielle Chiron, Helgi van de Velde, Joseph Mikhael
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 3, Pp 1-5 (2021)
Externí odkaz:
https://doaj.org/article/31f3b839f54a49c8a076edc5d8cd9bc3
Autor:
Rui Wang, Antoine Italiano, Shubham Pant, Johann De Bono, Todd M Bauer, Christophe Massard, Chia-Chi Lin, Roberto Iacovelli, Martin Gutierrez, Mansoor Saleh, Helen Lee, Gennaro Daniele, Paolo Andrea Zucali, Marielle Chiron, Bradley C Carthon, Robin Meng, Giovanni Abbadessa, Marcello Tucci, Wu-Chou Su, Alastair Greystoke, Ying-Chun Shen, Matteo Perrino, Yingwen Dong, Laure Loumagne, Lucie Lépine
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 1 (2022)
Externí odkaz:
https://doaj.org/article/77a4d7bd1ff24db7bd8825f9ede35742
Publikováno v:
BMC Bioinformatics, Vol 21, Iss 1, Pp 1-27 (2020)
Abstract Background Gene expression signatures for the prediction of differential survival of patients undergoing anti-cancer therapies are of great interest because they can be used to prospectively stratify patients entering new clinical trials, or
Externí odkaz:
https://doaj.org/article/4ce95414155744f2978564b39833a92b
Autor:
Etienne Rouleau, Jean-Yves Scoazec, Aurélien Marabelle, Benjamin Besse, David Planchard, Jack Pollard, Angelique Biancotto, Marielle Chiron, Nathalie Chaput-Gras, DIB Colette, Eladio Marquez, Joon Sang Lee, Shu Yan, Cecile Combeau, Félix Blanc-Durand, Mihaela Aldea, Ludovic Lacroix, Saloomeh Rafie, Eric Angevin
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/eec93b5ed5454a5b9e6ce5c07f948486
Autor:
Yannis Morel, Eric Vivier, Benjamin Rossi, Laurent Gauthier, Anne-Laure Bauchet, Ariane Morel, Marielle Chiron, Angela Virone-Oddos, Jochen Beninga, Céline Nicolazzi, Céline Amara, Audrey Blanchard-Alvarez, Nicolas Gourdin, Jacqueline Courta, Alexandra Basset, Franceline Guillot, Gwendoline Grondin, Hélène Bonnevaux
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/a67c4a2df1c3401e92f632956b1f8420
Autor:
Raja Rajalingam, Haibo Sun, Thomas G Martin, John Marra, Denice Kong, Jonathon Keats, Sandrine Macé, Marielle Chiron, Jeffrey L Wolf, Jeffrey M Venstrom
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 7 (2021)
Background Phase IIb clinical trial with isatuximab (Isa)-lenalidomide (Len)-dexamethasone (Dex) showed an improved progression-free survival (PFS) in patients with relapsed or refractory multiple myeloma (RRMM), but the efficacy varied by patient. A
Externí odkaz:
https://doaj.org/article/382f5cea13a14c7e88ccbe2c95aa6edc
Autor:
Chen Zhu, Zhili Song, Anlai Wang, Srimathi Srinivasan, Guang Yang, Rita Greco, Joachim Theilhaber, Elvis Shehu, Lan Wu, Zhi-Yong Yang, Wilfried Passe-Coutrin, Alain Fournier, Yu-Tzu Tai, Kenneth C. Anderson, Dmitri Wiederschain, Keith Bahjat, Francisco J. Adrián, Marielle Chiron
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
Isatuximab is a monoclonal antibody targeting the transmembrane receptor and ectoenzyme CD38, a protein highly expressed on hematological malignant cells, including those in multiple myeloma (MM). Upon binding to CD38-expressing MM cells, isatuximab
Externí odkaz:
https://doaj.org/article/c6c673aa2cd34bed8e6c98d6ee4b2379
Autor:
Btissam Chami, Makoto Okuda, Morvarid Moayeri, France Pirenne, Yoko Hidaka, Ashok Nambiar, Zhili Song, Olivier Bedel, Bailin Zhang, Joern Hopke, Gejing Deng, Chen Zhu, Sandrine Macé, Marielle Chiron, Francisco Adrian, Taro Fukao, Frank G. Basile, Thomas Martin
Publikováno v:
Transfusion. 62:2334-2348
There are two FDA-approved anti-CD38 monoclonal antibodies for treatment of multiple myeloma: isatuximab and daratumumab. Owing to expression of CD38 on reagent red blood cells (RBCs), these antibodies interfere with indirect antiglobulin tests (IATs
Autor:
Donald A. Bergstrom, Nina Baltes, Catherine Geslin, Loïc Vincent, Christophe Henry, Parminder K. Mankoo, Jack Pollard, Rebecca G. Bagley, Marielle Chiron
The recombinant fusion protein aflibercept (ziv-aflibercept in the United States) binds VEGF-A, VEGF-B, and placental growth factor (PlGF). The monoclonal antibody bevacizumab binds VEGF-A. Recent studies hypothesized that dual targeting of VEGF/PlGF
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0436a22971eef8a9ed9207a5d2029609
https://doi.org/10.1158/1535-7163.c.6536281
https://doi.org/10.1158/1535-7163.c.6536281